The Clustering of mApoE Anti-Amyloidogenic Peptide on Nanoparticle Surface Does Not Alter Its Performance in Controlling Beta-Amyloid Aggregation

Abstract

The deposition of amyloid-β (Aβ) plaques in the brain is a significant pathological signature of Alzheimer’s disease, correlating with synaptic dysfunction and neurodegeneration. Several compounds, peptides, or drugs have been designed to redirect or stop Aβ aggregation. Among them, the trideca-peptide CWG-LRKLRKRLLR (mApoE), which is derived from the receptor binding sequence of apolipoprotein E, is effectively able to inhibit Aβ aggregation and to promote fibril disaggregation. Taking advantage of Atomic Force Microscopy (AFM) imaging and fluorescence techniques, we investigate if the clustering of mApoE on gold nanoparticles (AuNP) surface may affect its performance in controlling Aβ aggregation/disaggregation processes. The results showed that the ability of free mApoE to destroy preformed Aβ fibrils or to hinder the Aβ aggregation process is preserved after its clustering on AuNP. This allows the possibility to design multifunctional drug delivery systems with clustering of anti-amyloidogenic molecules on any NP surface without affecting their performance in controlling Aβ aggregation processes.

Amyloid Arthropathy: A Review

“…This results in a ring-like birefringence on the surface of the deposits with polarized light. The composition and structure of amyloid deposits prevents proteolytic systems from breaking down the filaments 20,46,47…”

“…The composition and structure of amyloid deposits prevents proteolytic systems from breaking down the filaments. 20,46,47 The most common form of systemic amyloidosis is AL amyloidosis, with a reported incidence of 8.9 per million person years. 24,48,49 In AL amyloidosis, a neoplastic plasma cell clone synthesizes an abnormal monoclonal light chain that is deposited in all organs except the central nervous system.…”

The roles of prosaposin in neurological disorders: current understandings and prospects

“…The accumulation of Aβ plaques is a prominent pathological feature of AD, contributing to the neurodegenerative process (Corti et al, 2020). Aβ peptides, particularly Aβ 1-42 , are known to aggregate and form fibrillar plaques.…”

Clinical progress of nanomedicine-based RNA therapies

“…trehalose [ 90 ], targeting ligands, e.g. peptides, sugars, or antibodies [ [91] , [92] , [93] ], and/or endosomal escape moieties, e.g. trileucine [ 94 ], can potentially overcome these common issues.…”